AU657498B2
(en)
*
|
1990-12-14 |
1995-03-16 |
Novartis Ag |
Biphenylyl compounds
|
DE59208448D1
(de)
*
|
1991-08-15 |
1997-06-12 |
Ciba Geigy Ag |
N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten
|
US5260325A
(en)
*
|
1991-08-19 |
1993-11-09 |
E. I. Du Pont De Nemours And Company |
Angiotensin II receptor blocking tertiary amides
|
US5252753A
(en)
*
|
1991-11-01 |
1993-10-12 |
Ortho Pharmaceutical Corporation |
Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
|
EP0549352B1
(fr)
*
|
1991-12-27 |
2000-03-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Composés tricycliques comme antagonistes de l'angiotensine II
|
US5378701A
(en)
*
|
1991-12-27 |
1995-01-03 |
Kyowa Hakko Kogyo |
Tricyclic compounds
|
IL104755A0
(en)
*
|
1992-02-17 |
1993-06-10 |
Ciba Geigy Ag |
Treatment of glaucoma
|
US5378715A
(en)
*
|
1992-02-24 |
1995-01-03 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
US5514696A
(en)
*
|
1992-05-06 |
1996-05-07 |
Bristol-Myers Squibb Co. |
Phenyl sulfonamide endothelin antagonists
|
US5312820A
(en)
*
|
1992-07-17 |
1994-05-17 |
Merck & Co., Inc. |
Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
|
US5420123A
(en)
*
|
1992-12-21 |
1995-05-30 |
Bristol-Myers Squibb Company |
Dibenzodiazepine endothelin antagonists
|
US5256658A
(en)
*
|
1993-01-15 |
1993-10-26 |
Ortho Pharmaceutical Corporation |
Angiotensin II inhibitors
|
FR2711367B1
(fr)
*
|
1993-10-19 |
1995-12-01 |
Roussel Uclaf |
Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
|
US5965732A
(en)
*
|
1993-08-30 |
1999-10-12 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
SK117996A3
(en)
*
|
1994-03-17 |
1997-03-05 |
Ciba Geigy Ag |
Pharmaceutical composition for treatment of diabetic nephropathy
|
JPH0853424A
(ja)
*
|
1994-08-11 |
1996-02-27 |
Kureha Chem Ind Co Ltd |
ベンズイミダゾールスルホン酸アミド誘導体
|
US5612359A
(en)
*
|
1994-08-26 |
1997-03-18 |
Bristol-Myers Squibb Company |
Substituted biphenyl isoxazole sulfonamides
|
US5760038A
(en)
*
|
1995-02-06 |
1998-06-02 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5780473A
(en)
*
|
1995-02-06 |
1998-07-14 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
ATE225657T1
(de)
*
|
1995-10-06 |
2002-10-15 |
Novartis Erfind Verwalt Gmbh |
Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
|
JPH09124620A
(ja)
|
1995-10-11 |
1997-05-13 |
Bristol Myers Squibb Co |
置換ビフェニルスルホンアミドエンドセリン拮抗剤
|
AU1600297A
(en)
*
|
1996-02-15 |
1997-09-02 |
Novartis Ag |
Aryl derivatives
|
US5856507A
(en)
*
|
1997-01-21 |
1999-01-05 |
Bristol-Myers Squibb Co. |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
HUP0002351A3
(en)
|
1996-02-20 |
2001-10-29 |
Bristol Myers Squibb Co |
Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them
|
DE69718146T2
(de)
|
1996-02-29 |
2003-10-02 |
Novartis Ag |
At1 rezeptor antagonist zur anregung von apoptosis
|
US5939446A
(en)
*
|
1996-04-09 |
1999-08-17 |
Bristol-Myers Squibb Co. |
Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
|
KR980002035A
(ko)
*
|
1996-06-17 |
1998-03-30 |
손경식 |
비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
|
GB9613470D0
(en)
*
|
1996-06-27 |
1996-08-28 |
Ciba Geigy Ag |
Small solid oral dosage form
|
AU6187898A
(en)
*
|
1997-01-30 |
1998-08-25 |
Bristol-Myers Squibb Company |
Method for preventing or treating low renin hypertension by administering an endothelin antagonist
|
TW536540B
(en)
*
|
1997-01-30 |
2003-06-11 |
Bristol Myers Squibb Co |
Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
|
US6187796B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Sulfone hair growth compositions and uses
|
US20010049381A1
(en)
|
1997-06-04 |
2001-12-06 |
Gpl Nil Holdings, Inc., |
Pyrrolidine derivative hair growth compositions and uses
|
US6271244B1
(en)
|
1998-06-03 |
2001-08-07 |
Gpi Nil Holdings, Inc. |
N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
|
US6187784B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Pipecolic acid derivative hair growth compositions and uses
|
US5945441A
(en)
*
|
1997-06-04 |
1999-08-31 |
Gpi Nil Holdings, Inc. |
Pyrrolidine carboxylate hair revitalizing agents
|
US6274602B1
(en)
|
1998-06-03 |
2001-08-14 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioester and ketone hair growth compositions and uses
|
US6429215B1
(en)
|
1998-06-03 |
2002-08-06 |
Gpi Nil Holdings, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
AU1708099A
(en)
|
1998-06-03 |
1999-12-20 |
Amgen, Inc. |
N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
|
JP2002516846A
(ja)
*
|
1998-06-03 |
2002-06-11 |
ジーピーアイ ニル ホールディングス インコーポレイテッド |
小分子スルホンアミド発毛組成物および使用
|
US6331537B1
(en)
|
1998-06-03 |
2001-12-18 |
Gpi Nil Holdings, Inc. |
Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
|
US6172087B1
(en)
|
1998-06-03 |
2001-01-09 |
Gpi Nil Holding, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
DE69940063D1
(de)
*
|
1998-07-06 |
2009-01-22 |
Bristol Myers Squibb Co |
Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
SG142116A1
(en)
*
|
1998-07-10 |
2008-05-28 |
Novartis Ag |
Antihypersensitive combination of valsartan and calcium channel blocker
|
US6204281B1
(en)
|
1998-07-10 |
2001-03-20 |
Novartis Ag |
Method of treatment and pharmaceutical composition
|
US6465502B1
(en)
*
|
1998-12-23 |
2002-10-15 |
Novartis Ag |
Additional therapeutic use
|
EP1013273A1
(fr)
*
|
1998-12-23 |
2000-06-28 |
Novartis AG |
Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2
|
CZ297795B6
(cs)
|
1998-12-23 |
2007-03-28 |
Novartis Ag |
Tablety obsahující valsartan
|
CN101011390A
(zh)
*
|
1999-01-26 |
2007-08-08 |
诺瓦提斯公司 |
血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
|
PE20001456A1
(es)
*
|
1999-02-02 |
2001-01-28 |
Smithkline Beecham Corp |
Compuestos calcioliticos
|
KR20020004974A
(ko)
|
1999-03-19 |
2002-01-16 |
스티븐 비. 데이비스 |
비페닐 이속사졸 술폰아미드의 제조방법
|
US6395728B2
(en)
|
1999-07-08 |
2002-05-28 |
Novartis Ag |
Method of treatment and pharmaceutical composition
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
JP4374102B2
(ja)
*
|
1999-09-24 |
2009-12-02 |
住友化学株式会社 |
N,n−ジイソプロピルエチルアミンの分離方法
|
US6417189B1
(en)
|
1999-11-12 |
2002-07-09 |
Gpi Nil Holdings, Inc. |
AZA compounds, pharmaceutical compositions and methods of use
|
US7253169B2
(en)
|
1999-11-12 |
2007-08-07 |
Gliamed, Inc. |
Aza compounds, pharmaceutical compositions and methods of use
|
WO2001044239A2
(fr)
*
|
1999-12-15 |
2001-06-21 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline
|
EP1244670B1
(fr)
|
1999-12-21 |
2006-03-08 |
MGI GP, Inc. |
Composes a base de derives d'hydanto ne, compositions pharmaceutiques, et modes d'utilisation
|
US20020132839A1
(en)
*
|
2000-06-22 |
2002-09-19 |
Ganter Sabina Maria |
Tablet formulations comprising valsartan
|
WO2001097805A2
(fr)
*
|
2000-06-22 |
2001-12-27 |
Novartis Ag |
Compositions pharmaceutiques
|
PL205715B1
(pl)
|
2000-07-19 |
2010-05-31 |
Novartis Ag |
Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli
|
US20060089389A1
(en)
*
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
WO2003079972A2
(fr)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
US6639082B2
(en)
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
DE10059418A1
(de)
*
|
2000-11-30 |
2002-06-20 |
Aventis Pharma Gmbh |
Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
DE60132920T2
(de)
*
|
2000-12-26 |
2009-02-12 |
Pola Pharma Inc. |
Biphenylderivate
|
KR100926247B1
(ko)
*
|
2001-02-24 |
2009-11-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
|
NZ531346A
(en)
*
|
2001-08-28 |
2005-10-28 |
Sankyo Co |
Medicinal compositions containing angiotensin II receptor antagonist
|
US7468390B2
(en)
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
US6869970B2
(en)
|
2002-02-04 |
2005-03-22 |
Novartis Ag |
Crystalline salt forms of valsartan
|
US20040072886A1
(en)
*
|
2002-04-15 |
2004-04-15 |
Dr. Reddy's Laboratories Limited |
Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
|
WO2003089417A1
(fr)
*
|
2002-04-15 |
2003-10-30 |
Dr. Reddy's Laboratories Limited |
Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
|
EG24716A
(en)
*
|
2002-05-17 |
2010-06-07 |
Novartis Ag |
Combination of organic compounds
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
GB0222056D0
(en)
*
|
2002-09-23 |
2002-10-30 |
Novartis Ag |
Process for the manufacture of organic compounds
|
AU2003241836A1
(en)
|
2002-10-03 |
2004-04-23 |
Ono Pharmaceutical Co., Ltd. |
Lpa receptor antagonists
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
US7199144B2
(en)
|
2003-04-21 |
2007-04-03 |
Teva Pharmaceuticals Industries, Ltd. |
Process for the preparation of valsartan and intermediates thereof
|
DE602004013405T2
(de)
*
|
2003-03-17 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe formen von valsartan
|
EP1950204A1
(fr)
|
2003-03-17 |
2008-07-30 |
Teva Pharmaceutical Industries Ltd. |
Forme amorphe de valsartan
|
US20050165075A1
(en)
*
|
2003-03-31 |
2005-07-28 |
Hetero Drugs Limited |
Novel amorphous form of valsartan
|
US7010633B2
(en)
*
|
2003-04-10 |
2006-03-07 |
International Business Machines Corporation |
Apparatus, system and method for controlling access to facilities based on usage classes
|
WO2004094392A1
(fr)
*
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Processus de preparation de valsartan
|
WO2004094391A2
(fr)
*
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Procede de preparation du valsartan et de ses intermediaires
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
CZ298685B6
(cs)
*
|
2003-05-15 |
2007-12-19 |
Zentiva, A.S. |
Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
|
CA2526730A1
(fr)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Derives pyrroliques substitues
|
US7361770B2
(en)
*
|
2003-06-16 |
2008-04-22 |
Hetero Drugs Limited |
Process for preparation of valsartan
|
GB0316546D0
(en)
*
|
2003-07-15 |
2003-08-20 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
EP1658281B1
(fr)
*
|
2003-08-27 |
2010-09-29 |
Zentiva, k.s. |
Procede d'extraction du groupe protecteur de triphenylmethane
|
AU2004270162B2
(en)
*
|
2003-08-28 |
2010-05-13 |
Nicox S.A. |
Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
|
JP4537678B2
(ja)
*
|
2003-09-04 |
2010-09-01 |
住友化学株式会社 |
2’−(1h−テトラゾール−5−イル)ビフェニル−4−カルボアルデヒド結晶およびその製造方法
|
JP4829115B2
(ja)
*
|
2003-10-10 |
2011-12-07 |
ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
選択的i1イミダゾリンレセプターアゴニストおよびアンギオテンシンiiレセプターブロッカーを含有する医薬組成物
|
EP2428516A1
(fr)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Nouvelles substances thyromimetiques contenant du phosphore
|
WO2005049587A1
(fr)
*
|
2003-11-21 |
2005-06-02 |
Ranbaxy Laboratories Limited |
Procede de preparation de tetrazole de biphenyle
|
ITMI20032267A1
(it)
*
|
2003-11-21 |
2005-05-22 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Procdimento per la preparzione di valsartan e suoi intermedi
|
HRP20030965A2
(en)
*
|
2003-11-24 |
2005-08-31 |
Belupo - Lijekovi I Kozmetika D.D. |
Process for production of (s)-n-pentanoyl-n-[[2'-(
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
GB0402262D0
(en)
|
2004-02-02 |
2004-03-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US20080161321A1
(en)
|
2004-03-17 |
2008-07-03 |
David Louis Feldman |
Use of Renin Inhibitors in Therapy
|
ES2251292B1
(es)
*
|
2004-04-20 |
2007-07-01 |
Inke, S.A. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
|
EP1745800A4
(fr)
|
2004-04-26 |
2009-11-18 |
Ono Pharmaceutical Co |
Nouvelle maladie médiée par blt2, et agent et composé de liaison à blt2
|
CZ298471B6
(cs)
*
|
2004-05-19 |
2007-10-10 |
Zentiva, A.S. |
Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu
|
CN101119747A
(zh)
*
|
2004-07-02 |
2008-02-06 |
三共株式会社 |
组织因子产生抑制剂
|
EP1799199B1
(fr)
|
2004-10-08 |
2012-03-28 |
Novartis AG |
Utilisation d'inhibiteurs de renine pour la prevention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique
|
WO2006046593A1
(fr)
|
2004-10-27 |
2006-05-04 |
Daiichi Sankyo Company, Limited |
Composé du benzène ayant deux ou plus de deux substituants
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1838681A2
(fr)
|
2004-12-22 |
2007-10-03 |
Enantia, S.L. |
Composes intermediaires pour la preparation d'un antagoniste du recepteur de l'angiotensine ii
|
EA015108B1
(ru)
*
|
2004-12-24 |
2011-06-30 |
КРКА, д.д., НОВО МЕСТО |
Способ получения твердой фармацевтической композиции, содержащей валсартан
|
US7659406B2
(en)
*
|
2005-01-03 |
2010-02-09 |
Dr. Reddy's Laboratories Limited |
Process for preparing valsartan
|
CN101103006A
(zh)
*
|
2005-01-11 |
2008-01-09 |
特瓦制药工业有限公司 |
无定形缬沙坦的制备方法
|
US20060281801A1
(en)
*
|
2005-04-19 |
2006-12-14 |
Ashok Kumar |
Process for the preparation of valsartan and its intermediates
|
WO2007017897A2
(fr)
*
|
2005-05-25 |
2007-02-15 |
Ipca Laboratories Ltd. |
Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
|
US20070117987A1
(en)
*
|
2005-07-05 |
2007-05-24 |
Viviana Braude |
Process for preparing valsartan
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
AT502219B1
(de)
*
|
2005-08-04 |
2007-04-15 |
Sanochemia Pharmazeutika Ag |
Verfahren zur reindarstellung von 5-substituierten tetrazolen
|
WO2007019448A2
(fr)
*
|
2005-08-08 |
2007-02-15 |
Nitromed, Inc. |
Composes antagonistes de l'angiotensine ii amplifiant l'oxyde nitrique, compositions et methodes d'utilisation associees
|
ES2333169T3
(es)
*
|
2005-08-22 |
2010-02-17 |
Alembic Limited |
Procedimiento para la preparacion de valsartan.
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
WO2007057919A2
(fr)
*
|
2005-10-25 |
2007-05-24 |
Alembic Limited |
Procede ameliore pour la preparation de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
|
US20080227836A1
(en)
*
|
2005-10-31 |
2008-09-18 |
Lupin Ltd |
Stable Solid Oral Dosage Forms of Valsartan
|
SG166829A1
(en)
*
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US20070141533A1
(en)
*
|
2005-12-20 |
2007-06-21 |
Ford Christopher W |
Polymeric dental implant assembly
|
US20070166372A1
(en)
*
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
WO2007088558A2
(fr)
*
|
2006-02-02 |
2007-08-09 |
Alembic Limited |
Procédé de purification du valsartan
|
AR059838A1
(es)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
Formulaciones para dosis estabilizantes de estatina
|
NZ573360A
(en)
|
2006-05-04 |
2012-08-31 |
Boehringer Ingelheim Int |
Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP2021000A2
(fr)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenèse par modulation de l'angiotensine
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
CZ300801B6
(cs)
*
|
2006-06-07 |
2009-08-12 |
Helvetia Pharma A.S. |
Kompozice s valsartanem v pevných lékových formách
|
EP2043607A2
(fr)
*
|
2006-06-23 |
2009-04-08 |
Usv Limited |
Procédé de préparation de valsartan micronisé
|
US20080004313A1
(en)
*
|
2006-06-28 |
2008-01-03 |
Mai De Ltd. |
Preparation of crystalline polymorphs of rimonabant hydrochloride
|
US7880015B2
(en)
*
|
2006-07-03 |
2011-02-01 |
Aurobindo Pharma Ltd. |
Process for the preparation of angiotensin II antagonist
|
BRPI0714361A2
(pt)
*
|
2006-07-14 |
2013-03-26 |
Ranbaxy Lab Ltd |
polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
|
EP2474531A3
(fr)
*
|
2006-08-22 |
2013-12-04 |
Ranbaxy Laboratories Limited |
Inhibiteurs de métalloprotéase de matrice
|
EP1908469A1
(fr)
|
2006-10-06 |
2008-04-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
WO2008071400A1
(fr)
*
|
2006-12-14 |
2008-06-19 |
Ratiopharm Gmbh |
Procédé destiné à la préparation de valsartan et produits intermédiaires
|
JP5715339B2
(ja)
|
2007-01-12 |
2015-05-07 |
ノバルティス アーゲー |
5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法
|
TW200838501A
(en)
*
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
CA2679446C
(fr)
|
2007-03-01 |
2016-05-17 |
Probiodrug Ag |
Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
|
EP2139473A1
(fr)
*
|
2007-03-29 |
2010-01-06 |
Alembic Limited |
Formulations de comprimés de valsartan
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
TWI448284B
(zh)
*
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
KR20100021433A
(ko)
*
|
2007-05-07 |
2010-02-24 |
시플라 리미티드 |
발사르탄의 제조방법
|
US20080299218A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Protia, Llc |
Deuterium-enriched valsartan
|
EP2170930B3
(fr)
|
2007-06-04 |
2013-10-02 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
TWI406850B
(zh)
*
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
DE602007000211D1
(de)
*
|
2007-06-07 |
2008-12-11 |
Inke Sa |
Verfahren zur Gewinnung eines zur Gewinnung von Valsartan nützlichen Valsartan-Salzes
|
US8258312B2
(en)
|
2007-06-27 |
2012-09-04 |
Mylan Laboratories Ltd |
Process for preparing pure valsartan
|
GB0715628D0
(en)
*
|
2007-08-10 |
2007-09-19 |
Generics Uk Ltd |
Solid valsartan composition
|
EP2190434B1
(fr)
*
|
2007-08-17 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Utilisation de derives de la purine pour leur utilisation dans le traitement des maladies liees a fap
|
JP2010538071A
(ja)
|
2007-09-07 |
2010-12-09 |
セラヴァンス, インコーポレーテッド |
二重作用性降圧剤
|
KR101701109B1
(ko)
*
|
2007-10-05 |
2017-02-13 |
베라스템, 인코포레이티드 |
피리미딘 치환된 퓨린 유도체
|
KR20100091963A
(ko)
|
2007-10-09 |
2010-08-19 |
노파르티스 아게 |
발사르탄의 제약적 제형
|
CN101854913A
(zh)
|
2007-11-12 |
2010-10-06 |
诺瓦提斯公司 |
含有缬沙坦的液体组合物
|
JP2011506459A
(ja)
|
2007-12-11 |
2011-03-03 |
セラヴァンス, インコーポレーテッド |
抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
|
EP2240163A1
(fr)
*
|
2007-12-31 |
2010-10-20 |
Lupin Limited |
Compositions pharmaceutiques d'amlodipine et de valsartan
|
EP2090567A3
(fr)
|
2008-02-13 |
2011-06-01 |
Ranbaxy Laboratories Limited |
Processus pour la préparation d'intermédiaires de valsartan
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
US8492577B2
(en)
*
|
2008-04-07 |
2013-07-23 |
Hetero Research Foundation |
Process for preparation of valsartan intermediate
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
KR100995734B1
(ko)
|
2008-05-28 |
2010-11-19 |
일동제약주식회사 |
발사르탄의 개선된 제조방법
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2334651A2
(fr)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Agents anti-hypertensifs à double action
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP5906086B2
(ja)
*
|
2008-08-15 |
2016-04-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患の治療に用いるためのプリン誘導体
|
CN101362728B
(zh)
*
|
2008-08-22 |
2011-07-20 |
北京赛科药业有限责任公司 |
一种缬沙坦的合成方法
|
JP2012502081A
(ja)
|
2008-09-10 |
2012-01-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連症状の治療のための組み合わせ治療
|
WO2010042714A1
(fr)
*
|
2008-10-10 |
2010-04-15 |
Janssen Pharmaceutica Nv |
Thérapie d’association comprenant des inhibiteurs de récepteur d’angiotensine et antagonistes de récepteur de vasopressine
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
EP2194048A1
(fr)
|
2008-12-02 |
2010-06-09 |
Dirk Sartor |
Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
|
KR101012135B1
(ko)
|
2008-12-18 |
2011-02-07 |
주식회사 대희화학 |
발사르탄 메틸 에스테르의 제조방법
|
TWI508965B
(zh)
|
2008-12-23 |
2015-11-21 |
Boehringer Ingelheim Int |
有機化合物的鹽形式
|
WO2010075347A2
(fr)
|
2008-12-23 |
2010-07-01 |
Takeda Pharmaceutical Company Limited |
Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
|
CN101768128B
(zh)
*
|
2009-01-05 |
2012-10-10 |
浙江华海药业股份有限公司 |
一种含10%以上异构体的缬沙坦的精制方法
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CN101475540B
(zh)
*
|
2009-01-22 |
2011-05-11 |
江苏德峰药业有限公司 |
一种缬沙坦的制备方法
|
WO2010093601A1
(fr)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
|
JP5833000B2
(ja)
|
2009-07-07 |
2015-12-16 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
二重に作用するピラゾール抗高血圧症薬
|
US8372984B2
(en)
|
2009-07-22 |
2013-02-12 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
MX2012002993A
(es)
|
2009-09-11 |
2012-04-19 |
Probiodrug Ag |
Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
|
EP2316821A1
(fr)
|
2009-10-27 |
2011-05-04 |
Novartis AG |
Procédé pour la fabrication de composés organiques
|
JP2013512229A
(ja)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
|
WO2011090929A1
(fr)
|
2010-01-19 |
2011-07-28 |
Theravance, Inc. |
Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
|
KR101152144B1
(ko)
*
|
2010-02-01 |
2012-06-15 |
경동제약 주식회사 |
발사르탄의 제조 방법 및 이에 사용되는 신규 중간체
|
WO2011102702A2
(fr)
|
2010-02-16 |
2011-08-25 |
Krka, D. D., Novo Mesto |
Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
|
WO2011107530A2
(fr)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Nouveaux inhibiteurs
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
EP2556059B1
(fr)
*
|
2010-04-07 |
2014-05-07 |
KRKA, d.d., Novo mesto |
Procédé amélioré pour préparer du valsartan
|
CA2796710A1
(fr)
|
2010-04-19 |
2011-10-27 |
Cardiolynx Ag |
Derives de valsartan portant des donneurs d'oxyde d'azote dans le traitement de maladies vasculaires et metaboliques
|
EP2560953B1
(fr)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibiteurs de glutaminyl cyclase
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
US8981109B2
(en)
|
2010-07-02 |
2015-03-17 |
Aurobindo Pharma Ltd |
Process for the preparation of valsartan
|
TR201005419A2
(tr)
|
2010-07-05 |
2012-01-23 |
Bi̇lgi̇ç Mahmut |
Valsartan içeren farmasötik bileşim.
|
KR20130139863A
(ko)
|
2010-08-03 |
2013-12-23 |
노파르티스 아게 |
고도 결정질 발사르탄
|
WO2012025501A1
(fr)
|
2010-08-23 |
2012-03-01 |
Novartis Ag |
Procédé de préparation d'intermédiaires pour produire des inhibiteurs de l'endopeptidase neutre (epn)
|
CA2807830C
(fr)
|
2010-08-24 |
2018-04-03 |
Novartis Ag |
Traitement de l'hypertension et/ou prevention ou traitement de l'insuffisance cardiaque chez un mammifere recevant une therapie anticoagulante
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012056294A1
(fr)
|
2010-10-29 |
2012-05-03 |
Jubilant Life Sciences Ltd. |
Procédé amélioré de préparation de n-pentanoyl-n-[[2'-(1h-tétrazol-5-yl)[1,1'-biphényl]-4-yl]méthyl]-l-valine
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EP2675792B1
(fr)
*
|
2011-02-17 |
2016-01-06 |
Theravance Biopharma R&D IP, LLC |
Dérivés aminobutyriques substitués utilisés en tant qu'inhibiteurs de néprilysine
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
FR2977253B1
(fr)
|
2011-06-30 |
2013-08-09 |
Centre Nat Rech Scient |
Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
|
EP3517539B1
(fr)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Dérivé de quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement du diabète de type i et ii
|
KR101373705B1
(ko)
*
|
2011-08-05 |
2014-03-14 |
동국대학교 산학협력단 |
신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
EP2747757A1
(fr)
|
2011-08-26 |
2014-07-02 |
Wockhardt Limited |
Procédés de traitement de troubles cardiovasculaires
|
BR112014014527A2
(pt)
|
2011-12-15 |
2017-06-13 |
Takeda Pharmaceuticals Usa Inc |
combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
|
JP2015504878A
(ja)
|
2011-12-26 |
2015-02-16 |
ノバルティス アーゲー |
錠剤及び有核剤
|
WO2013098576A1
(fr)
|
2011-12-31 |
2013-07-04 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Composition pharmaceutique de valsartan à libération immédiate
|
WO2013098578A1
(fr)
|
2011-12-31 |
2013-07-04 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2844250B1
(fr)
|
2012-05-01 |
2017-11-08 |
Translatum Medicus Inc. |
Procédé de traitement et de diagnostic de maladies menant à la cécité
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
MA37850A1
(fr)
|
2012-08-24 |
2018-07-31 |
Novartis Ag |
Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
|
WO2014118721A1
(fr)
|
2013-01-30 |
2014-08-07 |
Ranbaxy Laboratories Limited |
Formes dosifiées solides orales pharmaceutiques comprenant du valsartan et du nébivolol
|
KR20140111982A
(ko)
|
2013-03-12 |
2014-09-22 |
주식회사 엘지생명과학 |
발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
WO2014151206A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
JP2016516804A
(ja)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
|
EP3004138B1
(fr)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
|
WO2015028941A1
(fr)
|
2013-08-26 |
2015-03-05 |
Novartis Ag |
Nouvelle utilisation
|
US20160206597A1
(en)
|
2013-08-26 |
2016-07-21 |
Toni Lynne Bransford |
New Use
|
WO2015056219A1
(fr)
|
2013-10-18 |
2015-04-23 |
Ranbaxy Laboratories Limited |
Procédé de séchage et de micronisation simultanés de valsartan
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
CN103923028B
(zh)
*
|
2014-05-04 |
2017-05-24 |
青岛雪洁助剂有限公司 |
一种缬沙坦甲酯的制备方法
|
CN104072386A
(zh)
*
|
2014-06-28 |
2014-10-01 |
浙江华海药业股份有限公司 |
一种缬沙坦中间体的改进方法
|
WO2016037552A1
(fr)
*
|
2014-09-09 |
2016-03-17 |
上海翰森生物医药科技有限公司 |
Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
JP6382736B2
(ja)
*
|
2015-02-02 |
2018-08-29 |
株式会社トクヤマ |
バルサルタンの製造方法
|
HRP20230480T1
(hr)
|
2015-05-11 |
2023-07-21 |
Novartis Ag |
Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
|
US20180140579A1
(en)
|
2015-05-29 |
2018-05-24 |
Novartis Ag |
Sacubitril and valsartan for treating metabolic disease
|
EP3828175A1
(fr)
|
2015-06-12 |
2021-06-02 |
Teva Pharmaceuticals International GmbH |
Formes à l'état solide de valsartan de trisodium : sacubitril
|
WO2017006254A1
(fr)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
|
SI3325013T2
(sl)
|
2015-07-23 |
2023-11-30 |
Bayer Pharma Aktiengesellschaft |
Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
|
JP6598985B2
(ja)
|
2015-08-28 |
2019-10-30 |
ノバルティス アーゲー |
新規の使用
|
US20190054069A1
(en)
|
2016-02-03 |
2019-02-21 |
Novartis Ag |
New use of a combination of sacubitril and valsartan
|
EP3468562A1
(fr)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinaisons de linagliptine et de metformine
|
WO2018002673A1
(fr)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
|
CN109641856B
(zh)
*
|
2016-09-02 |
2022-09-30 |
南京诺瑞特医药科技有限公司 |
缬沙坦二钠盐的晶型
|
CN107056720A
(zh)
*
|
2016-12-30 |
2017-08-18 |
湖南千金湘江药业股份有限公司 |
一种缬沙坦的制备和纯化方法
|
EP3342400A1
(fr)
|
2016-12-31 |
2018-07-04 |
Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. |
Composition pharmaceutique comprenant de la valsartane et du chlorthalidone
|
WO2018153895A1
(fr)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
|
JP7050893B2
(ja)
|
2017-07-07 |
2022-04-08 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ネコの全身性疾患の予防又は治療用アンジオテンシンii受容体拮抗薬
|
WO2019020706A1
(fr)
|
2017-07-28 |
2019-01-31 |
Synthon B.V. |
Composition pharmaceutique comprenant du sacubitril et du valsartan
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
EP3498698A1
(fr)
|
2017-12-15 |
2019-06-19 |
Mankind Pharma Ltd |
Formes solides de valsartan disodium et son procédé de préparation
|
WO2019200181A1
(fr)
|
2018-04-11 |
2019-10-17 |
Ohio State Innovation Foundation |
Procédés et compositions pour microparticules à libération prolongée pour l'administration de médicament oculaire
|
US11081240B2
(en)
|
2018-06-14 |
2021-08-03 |
Astrazeneca Uk Limited |
Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
|
US20210177803A1
(en)
|
2018-08-23 |
2021-06-17 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(fr)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
Nouvelles combinaisons de médicaments
|
US11413275B1
(en)
|
2018-12-14 |
2022-08-16 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
US10478422B1
(en)
|
2018-12-14 |
2019-11-19 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
US10548838B1
(en)
|
2018-12-14 |
2020-02-04 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
EP3911648A4
(fr)
|
2019-01-18 |
2022-10-26 |
Astrazeneca AB |
Inhibiteurs de pcsk9 et leurs procédés d'utilisation
|
US11446243B1
(en)
|
2019-08-05 |
2022-09-20 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
EP3939967A1
(fr)
|
2020-07-15 |
2022-01-19 |
KRKA, d.d., Novo mesto |
Procédé continu pour la préparation de (s)-méthyl n-((2'-cyano-[1,1'-biphényl]-4-yl)méthyl)-n-pentanoylvalinate dans un réacteur à écoulement
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
US11655220B2
(en)
|
2020-10-22 |
2023-05-23 |
Hetero Labs Limited |
Process for the preparation of angiotensin II receptor blockers
|
CN113387805B
(zh)
*
|
2021-07-21 |
2024-01-12 |
黑龙江立科新材料有限公司 |
基于烷基重氮盐取代反应的化合物的制备方法
|
WO2024019957A1
(fr)
*
|
2022-07-18 |
2024-01-25 |
Celgene Corporation |
Composés pour le traitement de maladies neurodégénératives
|